ClinicalTrials.gg
RecruitingNCT07467434SYNCHRONOXUpdated Jun 9, 2026

FOLFIRINOX Induction Chemotherapy for Synchronous Liver Metastases

An observational study in Rectal Cancer, Synchronous Liver Metastases and Antineoplastic Combined Chemotherapy Protocols, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
550
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 160 studies in Rectal Neoplasms with a site in France — 28 open to participants now, 40 under way, 6 of them phase 3. Rectal Neoplasms · France.

Planned enrollment
6th of 27
550 · median 100
Started
2026
with 6 others
Observational
27 of 160
10 open now
Primary completion
2030-11
later than 36 of 39 live
Registered
156th of 160
by date
Lead sponsor
9 of 160
Assistance Publique - Hôpitaux de Paris

Among the 160 studies in Rectal Neoplasms with a site in France, this one is the 6th largest by planned enrollment of the 27 observational ones that give a count, is one of 7 that started in 2026, is one of 27 observational ones, reaches primary completion later than 36 of the 39 other live ones, and was the 156th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

28 of the 160 studies in Rectal Neoplasms with a site in France are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 160 studies in Rectal Neoplasms with a site in France, or all of them as a file.
02

Study summary

SYNCHRONOX is a multicenter cohort (retrospective then prospective) intending to include 550 patients with mid or low rectal adenocarcinoma (pMMR, T3-T4 and/or N+) and resectable synchronous liver metastases, treated upfront with at least two cycles of induction FOLFIRINOX chemotherapy. The primary objective is to determine, at 18 months, the R0 resection rate of both tumor sites (rectum and liver), while secondary objectives focus on 3 year overall and progression free survival, radiological and pathological responses, postoperative morbidity and mortality, and comparison of the different surgical strategies after FOLFIRINOX.

Read the detailed description

SYNCHRONOX is a multicenter, observational retrospective cohort followed by a prospective validation cohort designed to evaluate therapeutic pathways and oncologic outcomes in adults with mid- or low-rectal adenocarcinoma and resectable synchronous liver metastases who received induction FOLFIRINOX chemotherapy. The study aims to describe and compare real-world management strategies after induction FOLFIRINOX (simultaneous rectum and liver surgery, "classic" rectum-first, "reverse" liver-first, and adaptive sequencing) and to identify factors associated with achieving complete curative-intent treatment of both tumor sites.

Eligible patients are ≥18 years old with pMMR mid/low rectal adenocarcinoma staged cT3-T4 and/or N+, with synchronous liver metastases diagnosed within 3 months before or after the rectal cancer diagnosis, without extrahepatic metastases, and treated with at least two cycles of induction FOLFIRINOX. Liver disease is considered resectable when lesions are unilobar (no limit in number) or bilobar with up to 10 lesions, corresponding to class I (clearly resectable with a conventional hepatectomy of ≤4 segments leaving >40% remnant liver) or class II (potentially resectable, requiring complex/extended liver surgery and possibly two-stage strategies). Because this is a non-interventional study, all diagnostic work-up, chemotherapy, radiotherapy, surgical decisions, and follow-up are performed as part of routine care and remain at the discretion of local multidisciplinary tumor boards. The research does not mandate any additional clinical, laboratory, radiologic examinations, surgical procedures, or questionnaires.

The primary endpoint is the rate of curative-intent complete treatment (R0) of both tumor sites at 18 months after the start of induction FOLFIRINOX. For rectal cancer, R0 resection is defined as a distal margin ≥1 cm and a circumferential resection margin >1 mm. Organ preservation without surgery is also considered curative-intent when achieved after a clinical complete response and not followed by tumor regrowth within the first year. For liver metastases, curative-intent treatment requires R0 resection of all visible lesions (margin >1 mm) and/or local destruction by radiofrequency ablation.

Secondary objectives include overall survival and progression-free survival at 3 years from the start of FOLFIRINOX, R0 resection rates for the rectal primary and liver metastases separately, radiologic response assessment at both sites (ymrTRG for rectal MRI response and RECIST for liver lesions), pathologic tumor regression grading (Rödel score for rectal cancer and Blazer classification for liver metastases), clinical complete response rate of the rectal tumor, and 30-day postoperative morbidity and mortality after rectal and liver surgery (Dindo-Clavien classification). Data are collected in an electronic case report form (eCRF) from standard medical records for both retrospective and prospective cohorts, with planned comparative analyses between strategies using matching variables and propensity-score methods to limit indication bias. The retrospective cohort includes patients diagnosed between June 1, 2020 and June 1, 2025, and the prospective validation cohort includes patients diagnosed between June 1, 2025 and June 1, 2028, with an overall follow-up duration of 60 months.

03

Conditions studied

  • Rectal Cancer
  • Synchronous Liver Metastases
  • Antineoplastic Combined Chemotherapy Protocols
  • Surgical Therapy

Browse trials for

Keywords

  • Prospective observational multicentric cohort
  • Retrospective observational multicentric cohort
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with mid/lower rectal cancer with resectable synchronous liver metastases, treated with FOLFIRINOX induction chemotherapy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subjects aged 18 years and older
  • Adenocarcinoma of the middle and/or lower rectum pMMR T3, T4, and/or N+
  • Resectable synchronous liver

Exclusion criteria

Exclusion Criteria:

  • Minor under the age of 18.
  • Presence of extrahepatic
  • Induction chemotherapy with FOLFIRINOX of less than 2 courses
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
550 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with rectal cancer with resectable synchronous liver metastases, treated with FOLFIRINOX

    Follow-up as part of the usual care of patients with mid/lower rectal cancer with resectable synchronous liver metastases, treated with FOLFIRINOX induction chemotherapy.

06

What researchers measure

Primary outcomes

  1. Curative resection rate of both tumor sites after induction chemotherapy with FOLFIRINOX

    For rectal cancer, resection is considered curative in cases of R0 resection (distal margin ≥ 1 cm and circumferential resection margin \> 1 mm). Non-surgical organ preservation is also considered curative treatment in cases of complete clinical response not followed by tumor regrowth during the first year. For liver metastases, resection is considered curative if all visible lesions have been resected R0 (resection margin \> 1 mm) or destroyed by radiofrequency.

    Time frame: 18 months from the start of chemotherapy with FOLFIRINOX

Secondary outcomes

  1. Overall 3-year survival rate

    The length of time from the start of FOLFIRINOX chemotherapy until death.

    Time frame: 3 years from the start of chemotherapy with FOLFIRINOX

  2. Three-year progression-free survival rate

    Survival is calculated from the start of treatment with FOLFIRINOX chemotherapy. Any progression during preoperative treatment preventing complete resection for curative purposes, the discovery of a contraindication to surgery during the operation, and the occurrence of recurrence after surgery will be considered an event.

    Time frame: 3 years from the start of chemotherapy with FOLFIRINOX

  3. Complete resection rate (R0) of rectal tumors

    Resection is considered complete (R0) if the distal margin is ≥ 1 cm and the circumferential resection margin is \> 1 mm.

    Time frame: 30 days after rectal resection

  4. Complete resection rate (R0) of liver lesions

    Resection is considered complete (R0) if the resection margin is \> 1 mm.

    Time frame: 30 days after liver resection

  5. Radiological response grade of rectal tumor to preoperative treatment

    The radiological response will be assessed using the Magnetic Resonance Tumor Regression Grade (ymrTRG), a five-grade scale ranging from 1 (complete response) to 5 (no response).

    Time frame: 1 month after the end of neoadjuvant therapy

  6. Radiological response grade of liver lesions to preoperative treatment

    The radiological response will be assessed using the RECIST score (partial response (response \> 30%), complete response (response 100%), progression (increase in lesion size \> 20%), stability (progression \< 20% and response \< 30%)).

    Time frame: 1 month after the end of FOLFIRINOX

  7. Histological response grade of rectal tumor to preoperative treatment

    The histological response grade will be assessed according to the Rödel score, a five-grade scale ranging from 0 (zero regression) to 4 (complete response).

    Time frame: 30 days after rectal resection

  8. Histological response grade of liver lesions to preoperative treatment

    The histological response grade is estimated according to Blazer. The Blazer score identifies three subgroups: 1. Complete response: absence of residual cancer cells; 2. Major response: presence of 1% to 49% of residual cancer cells; 3. Minor response: presence of ≥ 50% of residual cancer cells. In patients with multiple tumor nodules, the average of the values for the different nodules will be used to define the pathological response.

    Time frame: 30 days after liver resection

  9. Complete clinical response rate of rectal tumors

    Complete clinical response is defined by a complete radiological response on MRI (ymrTRG1) and no palpable lesion on digital rectal examination, and on endoscopy, no visible tumor or only a residual whitish scar without ulceration.

    Time frame: 1 month after neoadjuvant treatment

  10. Postoperative complication rate following rectal surgery

    Postoperative complication rates according to Dindo-Clavien (1=minor medical treatment; 2=antibiotic therapy, transfusion, parenteral nutrition; 3=surgical treatment, interventional radiology or endoscopy; 4=hospitalization in intensive care unit; 5=death).

    Time frame: 30 days post operative

  11. Postoperative complication rate following liver surgery

    Postoperative complication rates according to Dindo-Clavien (1=minor medical treatment; 2=antibiotic therapy, transfusion, parenteral nutrition; 3=surgical treatment, interventional radiology or endoscopy; 4=hospitalization in intensive care unit; 5=death).

    Time frame: 30 days post operative

  12. Postoperative mortality rate following rectal surgery

    Death within 30 days following rectal surgery.

    Time frame: 30 days post operative

  13. Postoperative mortality rate following liver surgery

    Death within 30 days following liver surgery.

    Time frame: 30 days post operative

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Nov 2030, 54 months after the start.

Of 214 non-industry observational studies under Rectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 118. This study's planned 54 months is above that.

Counting every sponsor, half of 229 studies reached it within 45 months; a quarter within 24 and three quarters within 116.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2026
First posted
Mar 12, 2026
StartActual
May 1, 2026
Primary completionEst.
Nov 1, 2030
CompletionEst.
May 1, 2034
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07467434
Responsible party
Sponsor
First posted
Mar 12, 2026
Start date
May 1, 2026
Primary completion
Nov 1, 2030 (estimated)
Completion
May 1, 2034 (estimated)
Last update
Jun 9, 2026

Study contacts

Stéphane BENOIST, MD PhD
Contact
stephane.benoist@aphp.fr
+33 (0)1 45 21 34 72
Solafah ABDALLA, MD PhD
Contact
solafah.abdalla@aphp.fr
+33 (0)1 45 21 34 70

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion